Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare TSE:AUPNYSE:BHCNASDAQ:CARANASDAQ:CRON On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAUPAurinia PharmaceuticalsC$0.00C$11.77▼C$26.00C$2.15BN/A229,895 shs4.61 million shsBHCBausch Health Cos$6.19+8.1%$4.94$3.96▼$9.85$2.29B0.282.63 million shs4.64 million shsCARACara Therapeutics$15.19$8.13▼$19.08$24.33M0.4124,282 shs237,144 shsCRONCronos Group$1.91$1.92$1.60▼$2.54$736.65M1.041.35 million shs1.11 million shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAUPAurinia Pharmaceuticals0.00%0.00%0.00%0.00%0.00%BHCBausch Health Cos0.00%+11.79%+32.61%-13.57%-4.28%CARACara Therapeutics0.00%0.00%0.00%-6.67%+82.74%CRONCronos Group0.00%-4.02%-8.61%+6.70%-17.32%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAUPAurinia PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ABHCBausch Health Cos3.7716 of 5 stars1.92.00.04.04.13.30.6CARACara Therapeutics0.3273 of 5 stars0.00.00.04.20.60.80.0CRONCronos Group1.8732 of 5 stars0.05.00.00.01.10.02.5Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAUPAurinia Pharmaceuticals 0.00N/AN/AN/ABHCBausch Health Cos 1.86Reduce$7.4219.76% UpsideCARACara Therapeutics 0.00N/AN/AN/ACRONCronos Group 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest CRON, AUP, BHC, and CARA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/2/2025BHCBausch Health CosRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetSector Perform ➝ Sector Perform$8.50 ➝ $10.004/7/2025BHCBausch Health CosRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSector Perform$9.00 ➝ $8.50(Data available from 6/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAUPAurinia PharmaceuticalsC$57.59M0.00N/A6.75C$2.59 per share0.00BHCBausch Health Cos$9.63B0.24$7.74 per share0.80($0.89) per share-6.96CARACara Therapeutics$7.14M0.00N/AN/A$12.58 per share0.00CRONCronos Group$117.61M6.26$0.00 per share4,104.70$2.90 per share0.66Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAUPAurinia PharmaceuticalsN/A-C$1.48N/AN/AN/AN/AN/AN/AN/ABHCBausch Health Cos-$46M-$0.11N/A1.33N/A-0.41%-540.45%5.26%7/30/2025 (Estimated)CARACara Therapeutics-$118.51M-$21.01N/AN/AN/A-1,099.76%-367.97%-107.43%N/ACRONCronos Group$41.08M$0.1314.6963.6743.3139.69%-0.07%-0.07%8/6/2025 (Estimated)Latest CRON, AUP, BHC, and CARA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025CRONCronos Group$0.01$0.02+$0.01$0.02$45.44 million$33.62 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAUPAurinia PharmaceuticalsN/AN/AN/AN/AN/ABHCBausch Health CosN/AN/AN/AN/AN/ACARACara TherapeuticsN/AN/AN/AN/AN/ACRONCronos GroupN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAUPAurinia Pharmaceuticals2.6911.9311.02BHCBausch Health CosN/A1.350.97CARACara TherapeuticsN/A4.774.71CRONCronos GroupN/A27.8026.75Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAUPAurinia PharmaceuticalsN/ABHCBausch Health Cos78.65%CARACara Therapeutics44.66%CRONCronos Group8.71%Insider OwnershipCompanyInsider OwnershipAUPAurinia PharmaceuticalsN/ABHCBausch Health Cos8.05%CARACara Therapeutics3.10%CRONCronos Group7.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAUPAurinia Pharmaceuticals300128.40 millionN/ANot OptionableBHCBausch Health Cos20,700370.08 million340.29 millionOptionableCARACara Therapeutics804.57 million4.43 millionOptionableCRONCronos Group450385.68 million357.53 millionOptionableCRON, AUP, BHC, and CARA HeadlinesRecent News About These Companies3 Marijuana Stocks For Longterm InvestorsJune 11, 2025 | marijuanastocks.comCronos Group And 2 Other Noteworthy Penny Stocks On The TSXJune 9, 2025 | finance.yahoo.comCronos Group (NASDAQ:CRON) Sees Large Volume Increase - Here's What HappenedJune 6, 2025 | marketbeat.comMarijuana Stocks To Watch With Strong Market PotentialJune 6, 2025 | marijuanastocks.comCronos Group Inc. (NASDAQ:CRON) Short Interest Down 14.4% in MayJune 4, 2025 | marketbeat.comCronos Group Inc. (NASDAQ:CRON) Shares Acquired by Millennium Management LLCJune 3, 2025 | marketbeat.comCronos Group Inc. to Speak at the TD Cowen 9th Annual Future of the Consumer ConferenceJune 2, 2025 | financialpost.comCronos Group Inc. to Speak at the TD Cowen 9th Annual Future of the Consumer ConferenceJune 2, 2025 | investing.comCronos Group Inc. to Speak at the TD Cowen 9th Annual Future of the Consumer ConferenceJune 2, 2025 | globenewswire.comCronos Group Inc. (NASDAQ:CRON) Shares Sold by Two Sigma Investments LPJune 1, 2025 | marketbeat.comTidal Investments LLC Decreases Stock Holdings in Cronos Group Inc. (NASDAQ:CRON)May 22, 2025 | marketbeat.comCronos Group: Industry Fortress Balance Sheet And FCF Create A Solid Upside PotentialMay 22, 2025 | seekingalpha.comTop Marijuana Stocks In A Volatile MarketMay 21, 2025 | marijuanastocks.comCronos Reports Improved Financials For Q1-2025 As Demand Outpaces SupplyMay 17, 2025 | seekingalpha.comShareholders Can Be Confident That Cronos Group's (TSE:CRON) Earnings Are High QualityMay 16, 2025 | finance.yahoo.comCronos Group Inc. (NASDAQ:CRON) Q1 2025 Earnings Call TranscriptMay 10, 2025 | msn.comTop 3 Marijuana Stocks For Better Investing 2025May 9, 2025 | marijuanastocks.comCronos Group Inc. (CRON) Q1 2025 Earnings Call TranscriptMay 8, 2025 | seekingalpha.comCronos Group Reports 2025 First Quarter ResultsMay 8, 2025 | globenewswire.comNews Explorer — 21Shares Introduces an ETP Tracking Cronos to Facilitate Investment in the Blockchain EcosystemMay 8, 2025 | decrypt.co21Shares Launches ETP Linked to Crypto.com's CronosMay 8, 2025 | coindesk.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden DomeAnalysts Think These Stocks Could More Than Double in ValueBy Nathan Reiff | May 23, 2025View Analysts Think These Stocks Could More Than Double in ValueIntel’s Turnaround May Be the Best Bet No One’s WatchingBy Jeffrey Neal Johnson | May 30, 2025View Intel’s Turnaround May Be the Best Bet No One’s WatchingBullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsBy Thomas Hughes | May 27, 2025View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsMicron Joins Latest $200 Billion United States Investment By Gabriel Osorio-Mazilli | June 16, 2025View Micron Joins Latest $200 Billion United States Investment CRON, AUP, BHC, and CARA Company DescriptionsAurinia Pharmaceuticals TSE:AUPAurinia Pharmaceuticals Inc., a biopharmaceutical company, develops and commercializes therapies to treat various diseases with unmet medical need in Japan and China. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.Bausch Health Cos NYSE:BHC$6.19 +0.46 (+8.08%) Closing price 06/18/2025 03:59 PM EasternExtended Trading$6.26 +0.06 (+1.00%) As of 06/18/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in the United States. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products internationally. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; generic products; ortho dermatologic; and dentistry products in the United States. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.Cara Therapeutics NASDAQ:CARACara Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. It also develops Oral difelikefalin, which is in Phase II/III clinical trial to treat chronic pruritus with notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; Vifor Fresenius Medical Care Renal Pharma Ltd. development and commercialization of KORSUVA injection for the treatment of moderate-to-severe pruritus in adult patients undergoing hemodialysis; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.Cronos Group NASDAQ:CRON$1.91 0.00 (0.00%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$1.93 +0.02 (+1.05%) As of 06/18/2025 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cronos Group Inc. operates as a cannabinoid company that engages in the cultivation, production and marketing of cannabis products in Canada, Israel, and Germany. It offers dried flower, pre-rolls, oils, vaporizers, edibles, and cannabis tinctures under the Spinach, Lord Jones, and PEACE NATURALS brands. Cronos Group Inc. was founded in 2012 and is based in Toronto, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Robinhood Director Sells Millions, But HOOD Stock Eyes Gains Coinbase Stock Pops as Senate Passes GENIUS Stablecoin Bill Chime’s Smart IPO: Half the Valuation, Double the Strength 3 Tech Stocks With High and Rising Institutional Interest Salesforce Raises Prices: 3 Reasons Its Stock Price Will Follow Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
